We found a match
Your institution may have rights to this item. Sign in to continue.
- Title
Lower risk of cardiovascular events and death associated with initiation of sodium‐glucose cotransporter‐2 inhibitors versus sulphonylureas: Analysis from the CVD‐REAL 2 study.
- Authors
Goh, Su‐Yen; Kosiborod, Mikhail N.; Lam, Carolyn S. P.; Cavender, Matthew A.; Kohsaka, Shun; Norhammar, Anna; Birkeland, Kåre I.; Holl, Reinhard W.; Mauricio, Dídac; Tangri, Navdeep; Shaw, Jonathan E.; Thuresson, Marcus; Fenici, Peter; Kim, Dae Jung
- Abstract
4 Dave CV, Kim SC, Goldfine AB, Glynn RJ, Tong A, Patorno E. Risk of cardiovascular outcomes in patients with type 2 diabetes after addition of SGLT2 inhibitors versus sulfonylureas to baseline GLP-1RA therapy. Before matching, patients in the SGLT2 inhibitor group were younger, more likely to be on metformin/glucagon-like peptide-1 receptor agonists/insulin, and had lower rates of comorbid heart failure, microvascular disease, stroke and chronic kidney disease (Table S2). Keywords: cardiovascular disease; real-world evidence; SGLT2 inhibitor; sulphonylureas; type 2 diabetes EN cardiovascular disease real-world evidence SGLT2 inhibitor sulphonylureas type 2 diabetes 2402 2409 8 07/04/23 20230801 NES 230801 INTRODUCTION Sulphonylureas (SUs) are widely used in type 2 diabetes (T2D), particularly in resource-constrained regions. Lower risk of cardiovascular events and death associated with initiation of sodium-glucose cotransporter-2 inhibitors versus sulphonylureas: Analysis from the CVD-REAL 2 study.
- Subjects
CARDIOVASCULAR disease related mortality; CARDIOVASCULAR diseases risk factors; METFORMIN; ARRHYTHMIA
- Publication
Diabetes, Obesity & Metabolism, 2023, Vol 25, Issue 8, p2402
- ISSN
1462-8902
- Publication type
Article
- DOI
10.1111/dom.15092